NCT07894211

QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-10-26Est. Completion: 2029-03-26

Enrollment target: 270 participants

Contact

Hong Sun, Bachelorhong.sun@qilu-pharma.com +86-18106583128

Other microbiome trials you might be interested in

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungPhase 2Recruiting

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine CarcinomaUnresectable Extrapulmonary Neuroendocrine Carcinoma

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy…

Anchorage, United StatesEst. completion Oct 1, 2028

View Trial →

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)Recruiting

Neuroendocrine TumorsCarcinoma, Neuroendocrine

Background: Neuroendocrine neoplasm (NENs)are rare cancers arising from the neuroendocrine cells and can affect almost …

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.